Meeting
2018 ASCO Annual Meeting
Oxaliplatin plus capecitabine (XELOX) in the perioperative treatment of locally advanced gastric adenocarcinoma in combination with D2 gastrectomy (NEO-CLASSIC).
Authors
Tianshu Liu
Zhongshan Hospital, Fudan University, Shanghai, China
Tianshu Liu , Yiyi Yu , Yong Fang , Zhenbin Shen , Min Yan , Hui Cao , Yingbin Liu , Xuefei Wang , Yuehong Cui , Yan Wang , Fenlin Liu , Weidong Chen , Wei Li , Yihong Sun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT01880632
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4022)
DOI
10.1200/JCO.2018.36.15_suppl.4022
Abstract #
4022
Poster Bd #
211
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase III trial to evaluate the efficacy of neoadjuvant chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with adjuvant S-1 in locally advanced gastric cancer: Japan Clinical Oncology Group study JCOG1509 (NAGISA trial).
First Author: Masanori Tokunaga
Poster
2016 ASCO Annual Meeting
Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: Capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
First Author: Yan Wang
Poster
2016 ASCO Annual Meeting
A Randomized, multicenter, controlled study to compare perioperative chemotherapy of Oxaliplatin combined with TS-1(SOX) versus SOX or oxaliplatin with capecitabine(XELOX) as post-operative chemotherapy in locally advanced gastric adenocarcinoma with D2 dissection (RESOLVE Trial).
First Author: Jiafu Ji
Poster
2015 ASCO Annual Meeting
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma: The TCOG T3211 trial.
First Author: Ming-Huang Chen